How will the 35% price discount by Merck/Samsung Bioepis on their infliximab biosimilar, compared with the reference, influence stakeholder uptake?
Infliximab-abda (Renflexis), biosimilar to Janssen Biotech tumor necrosis factor inhibitor infliximab (Remicade), is being introduced into the US market at a list price of $753.39, which represents a 35% discount off the current list price of Remicade. Merck and Samsung Bioepis have made a bold move by introducing the second biosimilar to Remicade at a significant discount.
Remicade and its 2 biosimilars, infliximab-abda and infliximab-dyyb (Inflectra) are long term treatments that are, for the most part, administered under the medical benefit.
Celltrion’s and Pfizer’s Inflectra has struggled to capture market share from Remicade due to factors such as offering a low discount (15%) off the originator’s list price and not being able to overcome effective contracting strategies and additional discounts provided by Janssen. Remicade erosion was targeted to be somewhere between 10%-15% and the erosion has been only about 5% in Q2 2017, which is less severe than expected.
In order to successfully capture more of Remicade’s US market share and $4.84 B in annual sales, Merck and Samsung Bioepsis have offered a 35% discount off the list price of Remicade. This discount, which is more than double Inflectra’s discount, will influence commercial insurers to evaluate the opportunity and then perhaps implement medical benefit (as well as pharmacy benefit) formulary changes to prefer Renflexis over Remicade. Additionally, this discount may encourage organizations that administer these drugs (ie, health systems) to begin utilizing and stocking up on Renflexis. Under the current Medicare Part B coding and reimbursement policy for biosimilars, providers will likely profit from a good portion of the 20% price difference between Renflexis and Inflectra, which share the same billing code.
The introduction of a second biosimilar, and future biosimilars, to Remicade along with a favorable management by insurers and utilization by organizations administering these drugs will help advance price competition, increase market share for biosimilars, and improve access for patients in the United States. We will see over the course of 2017 and 2018 whether the discount offered by Merck and Samsung was enough to influence insurers to prefer the biosimilar over the innovator.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.